Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia

@article{Turncliff2014RelativeBA,
  title={Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia},
  author={Ryan Z. Turncliff and Marjie L. Hard and Yangchun Du and Robert Risinger and Elliot W. Ehrich},
  journal={Schizophrenia Research},
  year={2014},
  volume={159},
  pages={404-410}
}
View on Elsevier
doi.org
36 Citations
Highly Influential Citations
2
Background Citations
8
Methods Citations
5
Results Citations
5

Figures and Tables from this paper

36 Citations

Citation Type

Citation Type

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
TLDR
ALNCD demonstrated similar exposure and safety profiles between the two administration sites, suggesting that ALNCD can be given in either the gluteal or the deltoid muscles as a component of the 1-day initiation regimen for AL.
Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?
TLDR
A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia finds that Depot antipsychotics may increase adherence to medication, reducing recurrence and rehospitalisation in schizophrenia.
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model
TLDR
Data from the phase I study and the 2MPopPK model support the suitability of using the AL 1064 mg dose as a 2-month (q8wk) dose interval option for the treatment of schizophrenia.
Aripiprazole Lauroxil: A Review in Schizophrenia
TLDR
Aripiprazole lauroxil LAI therapy was generally well tolerated, with an adverse event profile consistent with that of oral aripipazole (with the exception of injection-site reactions), including a low propensity to cause metabolic disturbances.
Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
TLDR
There is no available data comparing ALLAI to other antipsychotics, and more head-to-head trials comparing different LAI formulations are needed, but based on the available data, ALLAI is an effective and safe option for treatment of schizophrenia.
Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil
  • L. Citrome
  • Psychology, Medicine
    Expert review of clinical pharmacology
  • 2016
TLDR
The overall tolerability profiles of both products are consistent with what is known about oral aripiprazole.
Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review
TLDR
Aripiprazole LAI may to be efficacious in reducing relapse of schizophrenia and bipolar disorder in the long term in stabilised patients and in improving symptoms of schizophrenia during its acute phase, with both monohydrate and lauroxil formulations showing efficacy.
Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
  • 2017
Aripiprazole Lauroxil
TLDR
The PopPK model and model-based simulations were effective means for evaluating aripiprazole lauroxil dosing regimens and management of missed doses and play an important role in determining the use of this long-acting antipsychotic in clinical practice.
Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia
TLDR
A single dose of ALNCD with a single 30-mg oral dose of aripiprazole provides an alternative initiation regimen for starting AL, and the pharmacokinetic profile of the 1- day initiation regimen was comparable to the 21-day initiation regimen.
...
1
2
3
4
...

References

SHOWING 1-10 OF 46 REFERENCES
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study
Risperidone Long‐Acting Injection: Pharmacokinetics Following Administration in Deltoid Versus Gluteal Muscle in Schizophrenic Patients
TLDR
Injection of LAI risperidone into the deltoid muscle can be considered an alternative route of administration, because del toid and gluteal injections are interchangeable in terms of drug exposure, with no additional safety or tolerability issues.
Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.
TLDR
Its dissociation from those receptors is very slow, such that in patients with serum aripiprazole concentrations in the range typical for clinical practice, D(2)/D(3) receptors must remain nearly saturated for as long as 1 week after the last dose.
Inconsistency in Risperidone Long‐Acting Injection Steady‐State Plasma Levels When Switching From Deltoid to Gluteal Administration
TLDR
Although one study demonstrated that GM and DM injections of RLAI were bioequivalent routes of administration and thus interchangeable, a case of a patient switched from DM and GM injection resulting in inconsistent risperidone and 9-hydroxy-risPeridone levels is reported, believed to be the first case reporting a difference in steady-state levels between R LAIDM and GM administration.
A Double-Blind, Randomized Comparative Study of Aripiprazole and Olanzapine in Patients with Schizophrenia
Deltoid injections of risperidone long-acting injectable in patients with schizophrenia.
TLDR
Intramuscular injections via the deltoid and gluteal sites are equivalent routes of administration of risperidone long-acting injectable with respect to local injection-site tolerability.
Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
TLDR
This study demonstrated that the long-acting naltrexone formulation was well tolerated, displayed predictable pharmacokinetics, and resulted in no meaningful drug accumulation upon multiple dosing.
Effects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole
TLDR
A single aripiprazole 15-mg dose was well tolerated and adjustment of the aripIPrazole dose does not appear to be required in populations with hepatic or renal impairment.
Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors
TLDR
These results, together with previous studies demonstrating partial agonist activity at serotonin 5-hydroxytryptamine (5-HT)1A receptors and antagonist activity at 5-HT2A receptors, support the identification of aripiprazole as a dopamine-serotonin system stabilizer.
Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia
...
1
2
3
4
5
...